- Prior Authorization: Acute Myeloid Leukemia:
Documented Diagnosis: Yes
Medical Test Required: Yes
Duration: 12 Month(s)
Reauthorization Required: Yes
- Orally administered anticancer medication.
- Acute Myeloid Leukemia:
Duration: 12 Month(s)
Documented Diagnosis: Yes
Medical Test Required: Yes
Reauthorization Required: Yes
Duration of Reauthorization: = 12 month(s)
Drug Policy Based On: 1 of FDA Approved Indications;NCCN Guidelines
Quantity Limit: N/A
Criteria for Reauthorization: No evidence of disease progression or unacceptable toxicity
Use of Biomarkers in Policy: IDH2 mutation
Diagnosis Types: 2 of >=60 years and not a candidate for intensive remission induction therapy;Acute myeloid leukemia;Medically accepted uses supported by NCCN Category 1, 2A or 2B level of evidence;Post Remission Therapy;Relapsed/Refractory acute myeloid leukemia
Excludes Coverage in Maintenance Setting: No
- Quantity Limit: limit maximum 1 EA PER 1 day(s)
|